Are you ready to dive into the world of groundbreaking biotechnology and the fight against chronic diseases? In this episode of BioTalk with Rich Bendis, we bring you an enlightening conversation with Dr. Nehal Mehta, Founder and CEO of Mobius Scientific, Inc. Dr. Mehta is not only a distinguished Professor of Medicine but also a visionary entrepreneur on a mission to revolutionize healthcare.
Join us as we explore the journey of Mobius Scientific, an early-stage biotechnology company with a transformative approach. Mobius is developing cutting-edge biologic therapies targeting the root cause of chronic diseases, starting with lipid accumulation. This innovative platform has the potential to change the lives of millions suffering from debilitating conditions.
Listen now via your favorite podcast platform:
Apple - https://apple.co/46NK9Kd
Google - https://bit.ly/3TlApUu
Spotify - https://spoti.fi/47N1MLN
Amazon Music - https://amzn.to/46P83VL
TuneIn - https://bit.ly/47Qhupk
Discover the remarkable story behind Mobius, from its scientific origins and unique name to Dr. Mehta's decision to venture into the world of entrepreneurship. We discuss the science and technology that sets Mobius apart, revealing its pivotal role in addressing age-related macular degeneration (AMD), a leading cause of blindness globally.
Meet the exceptional team and advisors that drive Mobius forward, and learn how the company secured its initial funding and gained visibility through strategic contests. Dr. Mehta shares critical milestones and future goals, providing insights into the promising future of Mobius and its mission to combat chronic diseases.
Throughout the episode, we'll also explore how the BioHealth Capital Region has supported the growth and development of Mobius.
Tune in now and be part of the movement to combat chronic diseases with Dr. Nehal Mehta and Mobius Scientific.
Dr. Mehta is a Professor of Medicine at the George Washington University School of Medicine and an adjunct Associate Professor at the University of Pennsylvania, where he served as the Founding Director of Inflammatory Risk Clinic within Cardiovascular Medicine. He is an expert in general cardiology, lipidology, and cardiovascular imaging. Dr. Mehta’s initial work demonstrated dysfunctional HDL in psoriasis. He subsequently moved to the National Institutes of Health as the Inaugural recipient of the Lasker Clinical Scholar Award where he served as Section Chief of Inflammation and Cardiometabolic Diseases at the NHLBI. He was Director of Cardiovascular Imaging at the NHLBI, and the founding Director and Principal Investigator of the largest cohort study studying psoriasis and cardiometabolic diseases. During that time, he also completed several randomized trials in humans on the impact of biologic therapy on vascular diseases. In 2018, he was awarded an NIH Director's Award for demonstrating that high-risk coronary plaque in humans was improved following treatment of their inflammatory disease opening up a new path to mitigating risk in populations with chronic inflammation.
Dr. Mehta has chaired multiple working groups and guideline groups to establish a standard of care for cardiovascular risk reduction in patients with chronic inflammation. Dr. Mehta was inducted into the American Society of Clinical Investigation in 2018 and received two lifetime achievement awards for his work in cardiovascular risk reduction in inflammation in 2020 (International Federation of Psoriasis and Psoriatic Arthritis) and 2023 (National Psoriasis Foundation). He serves as a board member of the American Society of Preventive Cardiology, and is active within the National Psoriasis Foundation, American Heart Association and American College of Physicians as a fellow and an active educator. In 2022, Dr. Mehta became Founder and CEO of Mobius Scientific, Inc, an early stage biotechnology company making medicines to target cholesterol removal from tissues. He resides in Washington DC with his wife and two daughters.